NL-OMON30989尚未招募不适用
An Open-Label, Single Dose Study to Investigate Striatal Dopamine D2 Receptor Binding of JNJ-37822681 Using [11C]Raclopride Positron Emission Tomography in Healthy Male Subjects - PET study
Johnson & Johnson Pharmaceutical0 个研究点目标入组 8 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male subjects between 18 - 55 years of age
- •BMI between 18 and 30 kg/m²
排除标准
- •History of, or currently active, significant illness or medical disorder
- •Yearly cumulative dose due to exposure to radiation above 10 mSv
- •Any significant MR abnormalities as determined by a neuroradiologist
- •Metal implants
- •Claustrophobia
- •History of epilepsy or fits or unexplained black-outs
- •Significant history of or current psychiatric or neurological disease
研究者
相似试验
进行中（未招募）
不适用
A single-dose study to assess the safety and the manner in which the body metabolizes (breaks down) and gets rid of cinacalcet HCl, specifically in children with kidney failure who are being treated with dialysis.Secondary hyperparathyroidism (HPT) in subjects with chronic kidney disease (CKD) receiving maintenance hemodialysis.MedDRA version: 18.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2009-017999-25-DEAmgen Inc12
进行中（未招募）
1 期
A single-dose study to assess the safety and the manner in which the body metabolizes (breaks down) and gets rid of cinacalcet HCl, specifically in children with kidney failure who are being treated with dialysis.Secondary hyperparathyroidism (HPT) in subjects with chronic kidney disease (CKD) receiving maintenance hemodialysis.MedDRA version: 14.1 Level: PT Classification code 10020708 Term: Hyperparathyroidism secondary System Organ Class: 10014698 - Endocrine disordersEUCTR2009-017999-25-GBAmgen Inc14
进行中（未招募）
不适用
A single-dose study to assess the safety and the manner in which the bodymetabolizes (breaks down) and gets rid of cinacalcet HCl, specifically inchildren with kidney failure who are being treated with dialysisSecondary hyperparathyroidism (HPT) in subjects with chronic kidneydisease (CKD) receiving maintenance hemodialysis.MedDRA version: 17.1Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2009-017999-25-Outside-EU/EEAAmgen Inc12
进行中（未招募）
1 期
A single-dose study to assess the safety and the manner in which the body metabolizes (breaks down) and gets rid of cinacalcet HCl, specifically in children with kidney failure who are being treated with dialysis.Secondary hyperparathyroidism (HPT) in subjects with chronic kidney disease (CKD) receiving maintenance hemodialysis.MedDRA version: 18.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2009-017999-25-BEAmgen Inc12
进行中（未招募）
1 期
Study to Evaluate the Safety and action of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less than 18 Years with Secondary Hyperparathyroidism (sHPT) Receiving Maintenance HaemodialysisSecondary Hyperparathyroidism (sHPT) Receiving Maintenance HaemodialysisMedDRA version: 19.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2015-005051-28-BEAmgen Inc10